Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Midazolam(click to collapse)
1/4 selected
Midazolam
Versed
Benzodiazepine Anxiolytic/Sedative (BZD) · C-IV
FDA-approved indications
- Pre-operative sedation/anxiolysis/amnesia (IV, IM, intranasal)
- Conscious sedation for diagnostic and therapeutic procedures (IV, IM, intranasal)
- Acute agitation management (IM preferred)
- Induction of general anesthesia (IV)
Off-label uses
- Acute psychomotor agitation (IM — emergency departments)
- Status epilepticus (intranasal Nayzilam)
- Palliative sedation
MechanismGABA-A receptor positive allosteric modulator
Half-life1-4 hours (typically 1.5-2.5 hours); shorter than other benzos
Decision GuideWhen to pick each / when to consider an alternative
Midazolam
Consider when
- Acute agitation requiring rapid IM sedation — ultra-short onset, multiple routes (IM preferred for acute behavioral emergencies)
- Procedural sedation/conscious sedation — FDA-indicated for pre-operative and procedural use
- Status epilepticus or seizure emergency — intranasal formulation (Nayzilam) available
- Need for short-duration sedation with predictable offset — t1/2 1.5-2.5 hours in most patients
Consider an alternative when
- Outpatient/oral use for anxiety or insomnia — midazolam is NOT appropriate for routine oral anxiolysis
- No resuscitation equipment available — BBW requires continuous monitoring and rescue capability for respiratory depression
- Concurrent opioid use — ABSOLUTE contraindication for IV use; profound respiratory depression risk
- Elderly or hepatically impaired — active metabolite 1-hydroxymidazolam accumulates; prolonged sedation risk
| Axis | Midazolam Benzodiazepine |
|---|---|
| Boxed Warnings | |
Respiratory depression (opioid / CNS depressant co-use) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Cognitive dulling / anterograde amnesia | |
| GI | |
Nausea / GI (general) | |
| Local | |
Application/injection-site reactions | |
| Drug-specific / distinctive axes | |
Hemodynamic effects (hypotension, cardiac arrest) only in Midazolam | |